Additionally, another ongoing phase 2 trial (NCT05513703) is evaluating Teliso-V monotherapy in previously untreated MET Amp NSQ NSCLC with no targetable mutations (EGFR, ALK, ROS1, BRAF-WT). This evidence concerns the gene EGFR and non-small cell lung carcinoma.